雷迪帕韦

Description

Ledipasvir · CAS 1256388-51-8 · C49H54F2N8O6. UNII 013TE6E4WV. LogP: 3.8; Dissociation Constants: pka1 = 4.0, pka2 = 5.0.

Identification

CAS Registry Number	1256388-51-8
PubChem CID	67505836
Molecular formula	C49H54F2N8O6
IUPAC name	methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
UNII (FDA)	013TE6E4WV

Computed Descriptors

Molecular Weight	889.0
XLogP3	7.4
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	12
Exact Mass	888.41343780
Monoisotopic Mass	888.41343780
Topological Polar Surface Area	175
Heavy Atom Count	65
Formal Charge	0

Physical & Chemical Properties

LogP	3.8
Dissociation Constants	pka1 = 4.0, pka2 = 5.0

Physical description & handling notes

• Ledipasvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA). At a dose of 120 mg twice daily (2.67 times the maximum recommended dosage), ledipasvir does not prolong QTc interval to any clinically relevant extent.

Regulatory Status

GHS notification summary	50% (1 / 2)

GHS Hazard Classification

GHS notification summary	50% (1 / 2)
Reported hazard statements	H371 (50%)

Documented Uses

• When used in combination with the antiviral medication [sofosbuvir], ledipasvir is indicated for the treatment of treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with the following conditions: - Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. - Genotype 1 infection with decompensated cirrhosis, in combination with [ribavirin]. - Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated
• Breast Feeding; Lactation; Milk, Human; Antiviral Agents; NS5A Inhibitors
• Avoid St. John's Wort. This herb induces PGP and may reduce the serum concentration of ledipasvir.
• Take separate from antacids. Take at least 4 hours before or after antacids.
• Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
• Established Pharmacologic Class [EPC] - Hepatitis C Virus NS5A Inhibitor

Synonyms

Ledipasvir; 1256388-51-8; GS-5885; GS5885; GS 5885; WHO 9796; 013TE6E4WV; CHEBI:85089; DTXSID90154829; HARVONI COMPONENT LEDIPASVIR; ledipasvirum; RefChem:798885; DTXCID8077320; Ledipasvir acetonate; Ledipasvir [USAN:INN]; MFCD25976756

Frequently Asked Questions

What are the CAS number and molecular formula of Ledipasvir?

CAS 1256388-51-8; molecular formula C49H54F2N8O6; molecular weight — g/mol.

What other names is Ledipasvir known by?

Ledipasvir, 1256388-51-8, GS-5885, GS5885, GS 5885, WHO 9796.

Is Ledipasvir classified as hazardous?

50% of GHS notifications report no hazard classification (1 of 2).

What are the key physical properties of Ledipasvir?

LogP: 3.8; Dissociation Constants: pka1 = 4.0, pka2 = 5.0.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.